379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor

Authors :: Gareth Betts
Natalie Bath
Mark Dudley
Tanner Johanns
Ahmed Galal
Samuel Saibil
Adrian Sacher
Spinner William
Alex Tipping
Jessica Tucci
Raymond Luke
Trupti Trivedi
Quan Lin
Karen Miller
Source :: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Publication Year :: 2020
Publisher :: BMJ Publishing Group, 2020.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools